Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2a Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates Living in a High-Burden Tuberculosis-Endemic Region

Trial Profile

Phase 2a Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates Living in a High-Burden Tuberculosis-Endemic Region

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs MTBVAC (Primary) ; BCG
  • Indications Tuberculosis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Biofabri
  • Most Recent Events

    • 18 Dec 2018 Planned End Date changed from 1 Jan 2020 to 1 Nov 2020.
    • 18 Dec 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Jan 2020.
    • 18 Dec 2018 Planned initiation date changed from 1 Jul 2018 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top